The Chemours Company

NYSE:CC Stock Report

Market Cap: US$2.6b

Chemours Balance Sheet Health

Financial Health criteria checks 1/6

Chemours has a total shareholder equity of $659.0M and total debt of $4.0B, which brings its debt-to-equity ratio to 605.8%. Its total assets and total liabilities are $7.5B and $6.8B respectively. Chemours's EBIT is $489.0M making its interest coverage ratio 1.9. It has cash and short-term investments of $596.0M.

Key information

605.8%

Debt to equity ratio

US$3.99b

Debt

Interest coverage ratio1.9x
CashUS$596.00m
EquityUS$659.00m
Total liabilitiesUS$6.80b
Total assetsUS$7.46b

Recent financial health updates

Chemours (NYSE:CC) Takes On Some Risk With Its Use Of Debt

Jul 18
Chemours (NYSE:CC) Takes On Some Risk With Its Use Of Debt

Recent updates

Not Many Are Piling Into The Chemours Company (NYSE:CC) Just Yet

Dec 05
Not Many Are Piling Into The Chemours Company (NYSE:CC) Just Yet

Chemours: Hasn't Been A Great Year, But The Long-Term Prospects Look Bright

Nov 21

Chemours' (NYSE:CC) Earnings Offer More Than Meets The Eye

Nov 12
Chemours' (NYSE:CC) Earnings Offer More Than Meets The Eye

Is It Too Late To Consider Buying The Chemours Company (NYSE:CC)?

Sep 25
Is It Too Late To Consider Buying The Chemours Company (NYSE:CC)?

Chemours: We're Back Down To Trough And A 'BUY'

Sep 01

Chemours: Upside After Irregularities, Good 2024-2026E

Jun 11

The Chemours Company's (NYSE:CC) Low P/S No Reason For Excitement

May 30
The Chemours Company's (NYSE:CC) Low P/S No Reason For Excitement

Drama At The Chemours Company Opens The Door For Upside

Mar 29

The Chemours Company (NYSE:CC) Not Doing Enough For Some Investors As Its Shares Slump 37%

Mar 01
The Chemours Company (NYSE:CC) Not Doing Enough For Some Investors As Its Shares Slump 37%

Chemours: The Case Amidst Board Trouble, I Say Buy The Weakness

Feb 29

Chemours (NYSE:CC) Has Announced A Dividend Of $0.25

Feb 17
Chemours (NYSE:CC) Has Announced A Dividend Of $0.25

Chemours: Technological Innovation Presents Excellent Opportunities For Growth

Dec 23

Chemours (NYSE:CC) Will Pay A Dividend Of $0.25

Oct 30
Chemours (NYSE:CC) Will Pay A Dividend Of $0.25

The Chemours Company (NYSE:CC) Shares Could Be 21% Above Their Intrinsic Value Estimate

Oct 28
The Chemours Company (NYSE:CC) Shares Could Be 21% Above Their Intrinsic Value Estimate

Chemours: Volatile Bottom Line Needs Consistency

Oct 06

The Chemours Company: Portfolio Optimization Resulting In Compounding Growth

Sep 19

Chemours (NYSE:CC) Takes On Some Risk With Its Use Of Debt

Jul 18
Chemours (NYSE:CC) Takes On Some Risk With Its Use Of Debt

Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

Jul 03
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

The Chemours Company: On A Nice Run

Jul 03

Financial Position Analysis

Short Term Liabilities: CC's short term assets ($3.1B) exceed its short term liabilities ($1.8B).

Long Term Liabilities: CC's short term assets ($3.1B) do not cover its long term liabilities ($5.0B).

Debt to Equity History and Analysis

Debt Level: CC's net debt to equity ratio (515.3%) is considered high.

Reducing Debt: CC's debt to equity ratio has increased from 486% to 605.8% over the past 5 years.

Debt Coverage: CC's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: CC's interest payments on its debt are not well covered by EBIT (1.9x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 23:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

The Chemours Company is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAlembic Global Advisors
David ColemanArgus Research Company
Ishan MajumdarBaptista Research